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Narrowing down protocolMitochondrial disorders have the highest incidence among congenital metabolic diseases, and are thought to
occur at a rate of 1 in 5000 births. About 25% of the diseases diagnosed as mitochondrial disorders in the ﬁeld
of pediatrics have mitochondrial DNA abnormalities, while the rest occur due to defects in genes encoded in
the nucleus. The most important function of the mitochondria is biosynthesis of ATP. Mitochondrial disorders
are nearly synonymous with mitochondrial respiratory chain disorder, as respiratory chain complexes serve a
central role in ATP biosynthesis. By next-generation sequencing of the exome, we analyzed 104 patientswithmi-
tochondrial respiratory chain disorders. The results of analysis to date were 18 patients with novel variants in
genes previously reported to be disease-causing, and 27 patients with mutations in genes suggested to be asso-
ciated in some way with mitochondria, and it is likely that they are new disease-causing genes in mitochondrial
disorders. This article is part of a Special Issue entitled Frontiers of Mitochondrial Research.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
1.1. Mitochondrial disorders
Mitochondrial disorders have the highest incidence among congen-
ital metabolic disorders, and are thought to occur at a rate of 1 in 5000
births [1]. The common view of mitochondrial disorders is that they in-
clude mitochondrial encephalopathy and myopathy, with onset due to
mitochondrial DNA defects inherited through the maternal line. In
fact, however, only about 25% of the diseases diagnosed asmitochondri-
al disorders in theﬁeld of pediatrics havemitochondrial DNAabnormal-
ities [2,3], while the rest occur due to defects in genes encoded in the
nucleus. Most cases are sporadic (do not have a clear genetic associa-
tion), and a majority of cases resulting from nuclear gene abnormalitiesdisorder; BN-PAGE, blue native
nt stemcells; LIMD, lethal infan-
of Homozygosity
s of Mitochondrial Research.
ke).
. Open access under CC BY-NC-ND licensare autosomal recessive. Mitochondrial DNA has a circular structure
with a length of 16.6 kbp, and encodes only 13 proteins [4]. These 13
proteins are part of the structural composition of complex I (7 proteins),
complex III (1 protein), complex IV (3 proteins) and complex V (2 pro-
teins) in the respiratory chain. They do not include any complex II struc-
tural proteins. The remaining genes encoded in mitochondrial DNA are
22 tRNAs and two ribosomal RNAs, and mitochondrial disorders due to
defects in these RNAs have also been reported. Meanwhile, a certain
amount of the gene products encoded in the nucleus exists in themito-
chondria, and roughly 1500 are thought to serve important roles in mi-
tochondrial function [5]. In this analysis, we focused on mitochondrial
disorders thought to occur due to defects in genes encoded in the nucle-
us.Mitochondria havemany functions, one of themost important being
biosynthesis of energy (ATP), and we assume for the following discus-
sion that mitochondrial disorders are nearly synonymous with mito-
chondrial respiratory chain disorders (MRCD), as respiratory chain
complexes [6] serve a central role in ATP biosynthesis.
1.2. Mitochondrial disorders of nuclear origin
As stated above, of the approximately 1500 genes encoded in the nu-
cleus that are thought to be involved in biosynthesis and mitochondrial
function, more than 100 have been reported to be causes of mitochon-
drial disorders [7–9] (Table 1). Among these, about 90% of genes have
an autosomal recessive inheritance pattern, and only a small portione.
Table 1
The genetic basis of MRCD.
.
.
.
.
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reported cases of mitochondrial disorders from defects in genes
encoded by the X chromosome. By function, these include genes in-
volved in the structural composition of the complexes andmitochondri-
al biosynthesis, genes involved in membrane composition, genes
involved in the synthesis and transport of nucleic acids, genes involved
in regulating the expression of mitochondrial DNA, and genes involved
in mitochondrial DNA replication.
We have actively analyzed the exomes of patients with MRCD in
order to identify the cause. Here, we brieﬂy describe our project and dis-
cuss the results of exome analyses performed to date, touching on some
of the problems that have been encountered.2. Outline of exome analysis project for MRCD patients
Fig. 1 outlines our current project. It is supported by the Ministry of
Education, Culture, Sports, Science and Technology's Research Program
of Innovative Cell Biology by Innovative Technology (Cell Innovation)
(http://www.cell-innovation.org/english/html/program/theme_010_
okazaki.html). First, analyses of enzyme activity [11], quantity and size
were performed usingﬁbroblasts frompatient skin or biopsy specimens
from diseased organs of patients suspected of having MRCD in clinical
practice [12]. Quantity and size were analyzed using blue native poly-
acrylamide gel electrophoresis (BN-PAGE) [13]. Next, among patients
in whom decreased enzyme activity or complex formation abnormali-
ties were seen biochemically, whole exome analysis was performed in
thosewith no knownmitochondrial DNA abnormalities, and the obtain-
ed candidate causal genes were conﬁrmed at the cellular level by rescue
experiment or othermethods, such as siRNAexperiment.Many patients
with mitochondrial disorders have primary symptoms in the central
nervous system, but brain biopsy in these patients is untenable. There-
fore, induced pluripotent stem (iPS) cells were created using ﬁbroblasts
from the skin of patients from whom informed consent was obtained.
These iPS cells were then differentiated into neurons and glia cells to re-
produce the pathology of mitochondrial dysfunction that occurs specif-
ically in the nervous system, based on the notion that this may lead to
treatment at the cellular level and ultimately to treatment in humans.3. Clinical diagnosis of MRCD
Mitochondria exist in all tissues, and symptomsare presented in var-
ious organs and/or pathological entities. In pediatric MRCD, symptoms
are broadly divided into: (1) encephalomyopathy symptoms; (2) gas-
trointestinal/hepatic symptoms; and (3) myocardial symptoms [14].
So-called “mitochondrial encephalomyopathy,” which has traditionally
been considered the main form of mitochondrial disease, belongs
among the relatively mild mitochondrial diseases and occurs mostly in
older people. Fig. 2 shows a breakdown of clinical diagnoses of mito-
chondrial disorders in our institute as of January 2013 [15]. Patients
with the traditionally described nerve andmuscle symptomsnumbered
111 in total, including 50 with Leigh syndrome, 11 with neurodegener-
ative disorders for which no clear cause could be identiﬁed, and 50with
so-called “mitochondrial encephalomyopathy.” These 111 patients
accounted for 40% of the total of 275 patients. Conversely, other forms
accounted for two-thirds of cases, amongwhich were 49 cases of lethal
infantile mitochondrial disease (LIMD). Together with non-lethal infan-
tile mitochondrial disease (NLIMD), which follows the same course but
in which patients survive beyond 1 year of age, the number reached 71,
and was by far the most common clinical diagnosis. LIMD encompasses
hyperlactacidemia occurring in the neonatal period together with mul-
tiple organ failure.Most cases have poor outcomes, and it is thought that
most of these patients died with the cause remaining unknown and no
diagnosis established. Next were mitochondrial disorders showing sin-
gle organ dysfunction only, such as mitochondrial hepatopathy (12%)
and cardiomyopathy (7%).4. Exome analysis of MRCD patients
As most mitochondrial diseases occur sporadically with only a few
cases discovered in one family line, linkage analysis using a large pedi-
gree cannot be applied, thus suggesting that we cannot use information
on chromosomal localization for causal gene identiﬁcation.When iden-
tifying disease-causing genes using bioinformatics analysis for exome
data, knowledge of the inheritance patterns is very important [16]. As
approximately 90% of MRCD-causing genes show a recessive mode of
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Fig. 1.Outline of exomeanalysis project forMRCDpatients. The ﬁrst step is ‘Sampling’, which refers to diagnosis and collection of samples frompatientswithmitochondrial disorders using
both spectrophotometric enzyme assay [11] and BN-PAGE [13]. The next step is ‘Disease-Associated Gene Search’ using exome analysis. In ‘Functional Analysis’ and ‘System Biology’, can-
didate causal genes are conﬁrmed at the cellular level by rescue experiment or othermeans. In ‘Imaging SystemDevelopment’, induced pluripotent stem cells are created using ﬁbroblasts
and differentiated into neurons and glia cells to reproduce the pathology ofmitochondrial dysfunction. Theﬁnal purpose of our project is integrative understanding of themolecularmech-
anisms of mitochondrial disorders.
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ing rare variants in a homozygous or compound heterozygous fashion.
Low priority is given to the analysis of genes showing mutation
in only one allele because patients and healthy control individualsLS
ND
MC
LIMD
NLIMD
MH
MCM
SIDS/SUD
othersCardiomyopathy
19 (7%)
Nerve and muscle 
symptoms 111 (40%)
LS 50
ND 11 
MC 50
IMD 71 (26%)
LIMD 49
NLIMD22
Hepatopathy
34 (12%)
SIDS/SUD 25 (9%)
N=275
Fig. 2. Breakdownof clinical diagnoses ofmitochondrial disorders in our institute as of Jan-
uary 2013. LS, Leigh syndrome; ND, neurodegenerative disorder; MC, mitochondrial
cytopathy; IMD, infantile mitochondrial disease (lethal and non-lethal); MH, mitochon-
drial hepatopathy; MCM, mitochondrial cardiomyopathy; SIDS, sudden infant death
syndrome; SUD, sudden unexpected death.harbored a comparable number of rare heterozygous alleles; we were
unable to prioritize dominant-acting genes.
Our current bioinformatics analysis pipeline is as follows: read align-
ment was performed with a Burrows–Wheeler Aligner (BWA, version
0.7.0) [17] using the 1000 Genomes project phase II reference genome
(hs37d5.fa). PCR duplicate reads were removed using Picard (version
1.89) (http://picard.sourceforge.net) and non-mappable reads were re-
moved using SAMtools (version 0.1.19) [18]. After ﬁltering out these
reads, the Genome Analysis Toolkit (GATK) version 2.4-9-nightly-
2013-04-12-g3fc5478 [19] was used to realign insertions and deletions,
and for quality recalibration and variant calling (UniﬁedGenotyper). De-
tected variants were annotated using ANNOVAR (version 2013Feb21)
[20] and custom ruby scripts. The effect of the mutations on protein
function was assessed by SIFT and GERP using dbNSFP [21]. The posi-
tions of mutations were based on RefSeq transcript sequences. Variants
were assessed by comparing allele frequencies in the dbSNP135, Exome
Sequencing Project (ESP5400) data set, and 1000 Genomes Projects
(based on phase 1 release v3 called from 20101123 alignments). As mi-
tochondrial disorders are rare, we excluded variants present in dbSNP
with a frequency N 0.1%. After ﬁltering out these variants, the VAAST
program [22] was used to create a candidate gene list in each patient
showing recessive characteristics.
As stated above, because mitochondrial disease patients have very
high heterogeneity, the number of patients sharing the same gene mu-
tation is quite low. Hence, attention should be directed towards remov-
ing these mutations from the disease candidates when the same amino
acid substitutions are shared among multiple patients in our study, be-
cause these variants are highly likely to be SNPs unique to the Japanese
population. Using these criteria, we are able to narrow down the num-
ber of variants to a mean of several genes for each patient. After listing
Annotate variants
Variant filtering
Convert to gene-level list
Genes previously reported to cause 
MRCD (knowledge driven)
Genes suggested to have some type of 
relationship with mitochondria 
(knowledge driven)
Others (ab initio)
0 ~ 1 genes/sample
0 ~ 3 genes/sample
118,700 variants/sample
23 genes/sample (Min. 11, Max 49)
Fig. 3. Narrowing down of gene mutations discovered by exome analysis. After ﬁltering
out variants with themethods described in the ‘Exome analysis ofMRCD patients’ section,
genes were divided into three categories: (1) those that have previously been reported to
cause MRCD; (2) those for which some relationship with mitochondria has been sug-
gested; and (3) others (ab initio).
18 (17%)
27 (26%)59 (57%)
(N = 104)
Fig. 4. Candidate genes with exome analysis for MRCD patients. Results of analysis for 104
patients to date (as of January 2013) are shown. Eighteen patients (17%) had variants pre-
viously reported to be disease-causing. Twenty-seven patients (26%) had mutations in
genes suggested to be associated somehowwithmitochondria. The remaining 59 patients
(57%) are highly likely to contain completely novel disease-causing mutations for which
no data have been obtained to date.
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ants are located within genes related to mitochondrial function. When
genes overlapped with those reported to be related to mitochondrial
function, we found that they were likely to be causative genes and
were further subjected to experimental analysis such as haplotype
phasing or functional assay including rescue experiments. To prepare
a list of genes reported to be related to mitochondria, we included
genes annotated as somehow related to mitochondria in the UniProt
(http://www.uniprot.org/) [23] database, as well as theMitoCarta data-
base (http://www.broadinstitute.org/pubs/MitoCarta/index.html) [24],
which includes approximately 1000 gene products listed with the use
of shotgun proteomics and mitochondrial localization analysis.
We also investigated whether there is Long Contiguous Stretch of
Homozygosity (LCSH) using Affymetrix SNP arrays in a majority of pa-
tients. Although no cases of consanguineous marriage were reported
in the interviews with the primary physician, about 5% of cases harbor
LCSH proven by SNP arrays. When homozygousmutations are localized
in these LCSH regions, the mutations are highly likely to be causative of
disease.Table 2
Functions of new disease-causing candidate genes for MRCD.
MtoX#1 Non-receptor tyrosine kinase
MtoX#2 Acyl-CoA thioesterase
MtoX#3 Fatty acid β oxidation
MtoX#4 tRNA synthetase
MtoX#5 ABC transporter superfamily
MtoX#6 ATR-dependent AMP-binding enzyme family
MtoX#7 Heme biosynthesis
MtoX#8 AAA ATPase family
MtoX#9 Pre-mRNA splicing factor
MtoX#10 Creatine kinase
MtoX#11 Synaptic transmission
MtoX#12 Synthesis of Coenzyme Q
MtoX#13 Heme biosynthetic process
MtoX#14 Citrate synthase family.
MtoX#15 Cholesterol metabolism
MtoX#16 Mitochondrial ﬁssion
MtoX#17 Muscle organ development
MtoX#18 Cholesterol biosynthetic process
MtoX#19 Ribosomal protein
MtoX#20 Tumor suppressor
MtoX#21 A component of complex I
MtoX#22 A protease, located in inner membrane
MtoX#23 Regulation of PDH
MtoX#24 Mitochondrial translation
MtoX#25 Queuosine biosynthetic process
MtoX#26 Mitochondrial carrier family
MtoX#27 Methyltransferase superfamilya5. Results of exome analysis for MRCD patients
The variants (mutations) found in the process of narrowing down
the gene mutations discovered to date are shown in Fig. 3. These
genes were narrowed down to the ﬁnal candidate genes and divided
into three categories: (1) those that have previously been reported to
cause MRCD; (2) those for which some relationship with mitochondria
has been suggested; and (3) others (ab initio). The results of analysis of
104 patients to date (as of January 2013) are shown in Fig. 4. Eighteen
patients (17%) had variants previously reported to be disease-causing.
Among these 18 patients, one had a homozygote of a previously report-
ed mutation and two had a compound heterozygote of a reported and a
novel mutation (data not shown). All other mutations found in this
study were new. Twenty-seven patients (26%) had mutations in genes
suggested to be associated somehowwith mitochondria, and it is likely
that they are novel disease-causing genes in mitochondrial disorders.
Table 2 lists the functions of the genes in these 27 cases. For the remain-
ing 59 cases, each patient has about 20 gene variants that are unique to
each patient, and it is necessary to conﬁrm whether any of these muta-
tions can actually cause the disease. These 59 patients are highly likely
to contain completely novel disease-causing mutations for which no
clues have been obtained to date. The biggest issue we currently face
is how to conﬁrm the disease-causing gene from these 20 gene variants
for each patient.6. Conclusion and future prospects
The above describes the progresswe havemade in exome analysis of
neonatal or infantile MRCD patients. While we have identiﬁed many
candidate genes, the causes of MRCD are extremely diverse and hetero-
geneous. Thus, in many cases, it is difﬁcult to demonstrate conclusively
that a mutation in a candidate gene is the true cause. We have per-
formed analyses focusing on cases in which a biochemical diagnosis
was established at the cellular level in addition to clinical symptoms
such as enzyme activity and complex formation abnormalities. None-
theless, conﬁrmation of the causal genes with rescue experiments or
other means is difﬁcult. In the future, it will be necessary to increase
the case number or search for patients with similar symptoms and sim-
ilar gene mutations in collaboration with researchers throughout the
world. We are currently conducting analyses of pediatric patients with
a focus on MRCD, and gene mutations (amino acid substitutions) har-
bored by patients of the childhood onset type are probably variants con-
ferring major damage on enzyme activity or protein function. Onset is
also thought to occur in adulthood rather than in childhood in some
cases of milder (hypomorphic: partial loss of function) variants with
the same gene defect. As these are thought to include nerve diseases,
1359A. Ohtake et al. / Biochimica et Biophysica Acta 1840 (2014) 1355–1359mental disorders, and diabetes or other metabolic diseases of unknown
cause, we plan to conduct research based on the assumption that such
cases include those caused by abnormalities in genes identiﬁed in
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